Brii Biosciences Yönetim

Yönetim kriter kontrolleri 1/4

Brii Biosciences CEO'su Zhi Hong, Jan2018 tarihinde atandı, in görev süresi 6.83 yıldır. in toplam yıllık tazminatı CN¥ 18.16M olup, şirket hissesi ve opsiyonları dahil olmak üzere 40.8% maaş ve 59.2% ikramiyelerden oluşmaktadır. şirketin hisselerinin 4.5% ine doğrudan sahiptir ve bu hisseler HK$ 34.54M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3 yıl ve 2.2 yıldır.

Anahtar bilgiler

Zhi Hong

İcra Kurulu Başkanı

CN¥18.2m

Toplam tazminat

CEO maaş yüzdesi	40.8%
CEO görev süresi	6.8yrs
CEO sahipliği	4.5%
Yönetim ortalama görev süresi	3yrs
Yönetim Kurulu ortalama görev süresi	2.2yrs

Son yönetim güncellemeleri

Recent updates

Brii Biosciences (HKG:2137) Is In A Good Position To Deliver On Growth Plans

Nov 19

Here's Why We're Not Too Worried About Brii Biosciences' (HKG:2137) Cash Burn Situation

Jul 26

Companies Like Brii Biosciences (HKG:2137) Are In A Position To Invest In Growth

Jan 12

We're Hopeful That Brii Biosciences (HKG:2137) Will Use Its Cash Wisely

Sep 20

We're Not Worried About Brii Biosciences' (HKG:2137) Cash Burn

Mar 24

CEO Tazminat Analizi

Zhi Hong'un ücretlendirmesi Brii Biosciences'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	-CN¥265m
Mar 31 2024	n/a	n/a	-CN¥220m
Dec 31 2023	CN¥18m	CN¥7m	-CN¥175m
Sep 30 2023	n/a	n/a	-CN¥251m
Jun 30 2023	n/a	n/a	-CN¥327m
Mar 31 2023	n/a	n/a	-CN¥405m
Dec 31 2022	CN¥14m	CN¥7m	-CN¥484m
Sep 30 2022	n/a	n/a	-CN¥1b
Jun 30 2022	n/a	n/a	-CN¥2b
Mar 31 2022	n/a	n/a	-CN¥3b
Dec 31 2021	CN¥65m	CN¥37m	-CN¥4b
Sep 30 2021	n/a	n/a	-CN¥4b
Jun 30 2021	n/a	n/a	-CN¥4b
Mar 31 2021	n/a	n/a	-CN¥3b
Dec 31 2020	CN¥22m	CN¥5m	-CN¥1b
Dec 31 2019	CN¥20m	CN¥4m	-CN¥521m

Tazminat ve Piyasa: Zhi 'nin toplam tazminatı ($USD 2.54M ), Hong Kong pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 233.82K ).

Tazminat ve Kazançlar: Zhi şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Zhi Hong (60 yo)

6.8yrs

Görev süresi

CN¥18,158,000

Tazminat

Dr. Zhi Hong, PhD, co-founded Brii Biosciences Limited in 2018 and serves as its Executive Chairman of the Board, Chief Executive Officer & Executive Director since 2018. Prior to starting Brii Bio, Dr. Ho...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Zhi Hong	Co-founder	6.8yrs	CN¥18.16m	4.5% HK$ 34.5m
Ankang Li	Chief Financial & Strategy Officer	3.6yrs	CN¥12.48m	0.20% HK$ 1.5m
Eleanor de Groot	Chief Technology Officer	2.3yrs	Veri yok	Veri yok
Brian Alvin Johns	Chief Scientific Officer	less than a year	Veri yok	Veri yok
Sarah Qiu	Associate Director of Investor Relations	no data	Veri yok	Veri yok
Karen Del Barrio Neuendorff	Chief People Officer & Head of Human Resources	2.8yrs	Veri yok	Veri yok
Coy Stout	Head of Patient Advocacy	3.2yrs	Veri yok	Veri yok
Lianhong Xu	Head of Discovery	no data	Veri yok	Veri yok
Qing Zhu	Head of China Research & Development	4.3yrs	Veri yok	Veri yok
David Margolis	Chief Medical Officer	4.1yrs	Veri yok	Veri yok
Susannah Cantrell	Chief Business Officer	2.3yrs	Veri yok	Veri yok
Aleksandar Skuban	Head of Central Nervous System Diseases Therapy Area Head	2.3yrs	Veri yok	Veri yok

3.0yrs

Ortalama Görev Süresi

55yo

Ortalama Yaş

Deneyimli Yönetim: 2137 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Zhi Hong	Co-founder	6.8yrs	CN¥18.16m	4.5% HK$ 34.5m
Ankang Li	Chief Financial & Strategy Officer	2.2yrs	CN¥12.48m	0.20% HK$ 1.5m
Yiu Wa Tsui	Independent Non-executive Director	no data	CN¥620.00k	0.012% HK$ 91.4k
Gregg Alton	Independent Non-executive Director	no data	CN¥620.00k	0.012% HK$ 91.4k
Taiyin Yang	Independent Non-Executive Director	2.2yrs	CN¥832.00k	0.030% HK$ 228.9k
Martin J. Murphy	Independent Non-executive Director	no data	CN¥620.00k	0.012% HK$ 91.4k
Hui Tang	Independent Non-executive Director	no data	CN¥620.00k	0.012% HK$ 91.4k

2.2yrs

Ortalama Görev Süresi

64yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 2137 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilmiyor ( 2.2 yıllık ortalama görev süresi), bu da yeni bir yönetim kurulu olduğunu gösteriyor.

Brii Biosciences Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Son yönetim güncellemeleri

Co-founder recently bought HK$59k worth of stock

Brii Biosciences Limited, Annual General Meeting, Jun 25, 2024

Brii Biosciences Limited Announces Executive Changes

High number of new directors

Brii Biosciences Limited Announces Executive Changes

Brii Biosciences Limited Announces Board and Committee Changes

Recent updates

Co-founder recently bought HK$59k worth of stock

New major risk - Revenue and earnings growth

New major risk - Revenue size

Brii Biosciences Limited to Report First Half, 2024 Results on Aug 19, 2024

New minor risk - Market cap size

Brii Biosciences Limited Announces New Data from Two Phase 2 Studies Evaluating BRII-179

Brii Biosciences Limited, Annual General Meeting, Jun 25, 2024

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Brii Biosciences Limited to Report Fiscal Year 2023 Results on Mar 22, 2024

New minor risk - Profitability

Forecast to breakeven in 2026

Brii Biosciences (HKG:2137) Is In A Good Position To Deliver On Growth Plans

PBrii Biosciences Limited Presents New Data Highlighting Progress Towards Achieving HBV Functional Cure at AASLD's The Liver Meeting 2023

New minor risk - Share price stability

Consensus EPS estimates upgraded to CN¥0.92 loss

Brii Biosciences Announces Topline Interim Results of Phase 2 Study Evaluating Brii-179 (Vbi-2601) in Combination with Peg-Ifn for the Treatment of Chronic Hepatitis B

Consensus revenue estimates increase by 2,527%

First half 2023 earnings released: CN¥0.26 loss per share (vs CN¥0.48 loss in 1H 2022)

Brii Biosciences Limited to Report First Half, 2023 Results on Aug 22, 2023

Here's Why We're Not Too Worried About Brii Biosciences' (HKG:2137) Cash Burn Situation

Brii Biosciences Limited Announces Executive Changes

Shionogi Inc. entered into a definitive agreement to acquire Qpex Biopharma, Inc. from Brii Biosciences Limited (SEHK:2137) and Others for $140 million.

Brii Biosciences Limited Announces Dosing of First Subject in Phase 1 Clinical Trial Evaluating BRII-297

Consensus revenue estimates fall by 100%

Forecast breakeven date pushed back to 2025

Forecast to breakeven in 2024

Brii Biosciences Limited Announces Interim Findings from A Phase 2 Study

Companies Like Brii Biosciences (HKG:2137) Are In A Position To Invest In Growth

No longer forecast to breakeven

Brii Biosciences Limited Provides Update on Strategic Clinical Development Progress

High number of new directors

Brii Biosciences Announces New Data from Two Phase 1 Studies

Brii Biosciences Limited Announces Topline Results from a Phase 1 Study Evaluating its Long-Acting, Single-Injection Therapy, BRII-296, in the Development for the Treatment of Postpartum Depression

We're Hopeful That Brii Biosciences (HKG:2137) Will Use Its Cash Wisely

Brii Biosciences Limited Announces Executive Changes

Brii Biosciences Limited Announces Board and Committee Changes

Brii Biosciences Limited Announces Board Changes

Consensus forecasts updated

No longer forecast to breakeven

Brii Biosciences Limited Appoints Eleanor De Groot as Senior Vice President and Chief Technology Officer and Aleksandar Skuban as Central Nervous System Diseases Therapy Area Head

Brii Biosciences Limited Appoints Eleanor De Groot as Chief Technology Officer and Aleksandar Skuban as Central Nervous System Diseases Therapy Area Head

Brii Biosciences Limited to Report First Half, 2022 Results on Aug 23, 2022

Brii Biosciences Announces Positive Data Demonstrating its Long-Acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, Retains Neutralizing Activity Against Live Omicron Virus BA.4/5 and BA.2.12.1 Subvariants

Brii Biosciences Appoints Dr. Susannah Cantrell as Chief Business Officer

Consensus revenue estimates increase by 14%

Brii Biosciences Limited Announces Commercial Launch of its Amubarvimab/Romlusevimab Combination Therapy for COVID-19 in China

Brii Biosciences Announces Positive Data from a Randomized, Single-Blind Study of its Long-Acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, in China

Forecast to breakeven in 2023

Brii Bio Announces Positive Data Demonstrating Its Long-Acting Covid-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, Retains Neutralizing Activity Against Omicron Ba.2 Subvariant

No longer forecast to breakeven

Insufficient new directors

Brii Biosciences Limited Presents New Data on BRII-835 (VIR-2218) in Chinese Patients with Chronic Hepatitis B at APASL 2022

Brii Biosciences Limited, Annual General Meeting, Jun 22, 2022

Brii Biosciences Limited, Annual General Meeting, Jun 22, 2022

We're Not Worried About Brii Biosciences' (HKG:2137) Cash Burn

Brii Biosciences Limited to Report Fiscal Year 2021 Results on Mar 22, 2022

Brii Bio Appoints Karen D. Neuendorff as Chief People Officer and Head of Human Resources

Brii Biosciences Limited Doses First Patient in Phase 2a/2b Clinical Trial of BrII-179 (VBI-2601) for the Functional Cure of Chronic Hepatitis B

Brii Biosciences Limited Announces Amubarvimab/Romlusevimab Combination Retains Neutralizing Activity Against Omicron SARS-CoV-2 Variant

Brii Bio Announces Amubarvimab/Romlusevimab Combination Received Approval from NMPA as First COVID-19 Neutralizing Antibody Combination Therapy in China

Brii Biosciences Announces Positive Data from the Phase 3 ACTIV-2 Trial Evaluating Combination BRII-196 and BRII-198 in Non-Hospitalized COVID-19 Patients

Brii Biosciences Announces Completion of Enrollment in the Phase 3 National Institutes of Health ACTIV-2 Trial, Evaluating the BRII-196 and BRII-198 Monoclonal Neutralizing Antibody Combination for the Treatment of COVID-19

Brii Biosciences Limited has completed an IPO in the amount of HKD 2.482655 billion.

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi